Role of Cytochrome P450 Enzymes in Pediatric Drug Metabolism: Physiological and Biochemical Perspectives; Systematic Review
Role of Cytochrome P450 Enzymes in Pediatric Drug Metabolism
DOI:
https://doi.org/10.54393/pjhs.v7i5.3930Keywords:
Cytochrome P450, Pediatrics, Ontogeny, Pharmacogenetics, Pharmacokinetics, Therapeutic Drug MonitoringAbstract
Cytochrome P450 (CYP450) enzymes are central to pediatric drug metabolism. However, enzyme maturation (ontogeny) and pharmacogenetic variability produce substantial age-dependent differences in drug clearance, exposure, and toxicity risk across neonatal, infant, and childhood populations. Objectives: To synthesize contemporary evidence (2020–2025) on CYP450 ontogeny and pharmacogenetic variability in children and evaluate their clinical implications for drug clearance, dosing optimization, and safety. Methods: A systematic review was conducted according to PRISMA 2020 guidelines. PubMed, Scopus, Web of Science, and Google Scholar were searched for pediatric studies evaluating CYP450 ontogeny, pharmacokinetics, or pharmacogenetics. Eligible designs included observational studies, physiologically based pharmacokinetic (PBPK)/population PK modeling, real-world analyses, and systematic reviews. Risk of bias was assessed using the Newcastle–Ottawa Scale and AMSTAR. Due to heterogeneity, findings were synthesized narratively. Results: Sixteen studies from Asia, Europe, North America, and Australia were included. CYP2C19, CYP3A4, and CYP2D6 were the most frequently investigated isoforms. Ontogeny demonstrated enzyme-specific maturation patterns: CYP3A4 and CYP2C19 activity increased rapidly during infancy, whereas CYP2D6 and CYP1A2 matured more gradually, contributing to reduced neonatal clearance and prolonged half-life of several substrates. Clinically significant genotype–drug interactions were consistently reported for CYP2D6–codeine and CYP2C19–voriconazole/proton pump inhibitors, where poor or ultrarapid metabolizer phenotypes markedly altered exposure and toxicity risk. Evidence supports genotype-guided dosing and therapeutic drug monitoring for selected high-risk drugs. Conclusions: Pediatric drug clearance is governed by enzyme-specific maturation and functional polymorphisms. Integrating developmental dosing principles with targeted pharmacogenetic strategies may improve therapeutic precision and reduce avoidable toxicity in children.
References
Hossam Abdelmonem B, Abdelaal NM, Anwer EK, Rashwan AA, Hussein MA, Ahmed YF et al. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines. 2024 Jul; 12(7): 1467. doi: 10.3390/biomedicines12071467.
Emoto C and Johnson TN. Cytochrome P450 Enzymes in the Pediatric Population: Connecting Knowledge on P450 Expression with Pediatric Pharmacokinetics. In Advances in Pharmacology. 2022 Jan; 95: 365-391. doi: 10.1016/bs.apha.2022.05.006.
Kamran SH, Rehman K, Akash MS, Khan A, Laher I. Impact of Physiological Factors on Drug-Metabolizing Enzymes: From Function to Regulation. In Biochemistry of Drug Metabolizing Enzymes. 2022 Jan: 281-304. doi: 10.1016/B978-0-323-95120-3.00003-8.
Konstandi M and Johnson EO. Age-Related Modifications in CYP-Dependent Drug Metabolism: Role of Stress. Frontiers in Endocrinology. 2023 May; 14: 1143835. doi: 10.3389/fendo.2023.1143835.
Watanabe H, Nagano N, Tsuji Y, Noto N, Ayusawa M, Morioka I. Challenges of Pediatric Pharmacotherapy: A Narrative Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. European Journal of Clinical Pharmacology. 2024 Feb; 80(2): 203-21. doi: 10.1007/s00228-023-03598-x.
Bansal N, Momin S, Bansal R, Gurram Venkata SK, Ruser L, Yusuf K. Pharmacokinetics of Drugs: Newborn Perspective. Pediatric Medicine. 2023; 7. doi: 10.21037/pm-22-11.
Tang LW and Chan EC. Metabolic Activation of Drugs by Cytochrome P450 Enzymes: Biochemical Insights into Mechanism-Based Inactivation by Fibroblast Growth Factor Receptor Inhibitors and Chemical Approaches to Attenuate Reactive Metabolite Formation. Biochemical Pharmacology. 2022 Dec; 206: 115336. doi: 10.1016/j.bcp.2022.115336.
Zhang W, Zhang Q, Cao Z, Zheng L, Hu W. Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives. Pharmaceutics. 2023 Dec; 15(12): 2765. doi: 10.3390/pharmaceutics15122765.
Goldman GS and Cheng RZ. The Immature Infant Liver: Cytochrome P450 Enzymes and Their Relevance to Vaccine Safety and SIDS Research. International Journal of Medical Sciences. 2025 Apr; 22(10): 2434. doi: 10.7150/ijms.114402.
Kim H and Park HJ. Current hPSC-derived Liver Organoids for Toxicity Testing: Cytochrome P450 Enzymes and Drug Metabolism. Toxicological Research. 2025 Mar; 41(2): 105-21. doi: 10.1007/s43188-024-00275-8.
Iacopetta D, Ceramella J, Catalano A, Scali E, Scumaci D, Pellegrino M et al. Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs. Applied Sciences. 2023 May; 13(10): 6045. doi: 10.3390/app13106045.
Johnson TN, Howgate EM, de Wildt SN, Turner MA, Yeo KR. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny in Vivo. Drug Metabolism and Disposition. 2023 Aug; 51(8): 1035-45. doi: 10.1124/dmd.123.001270.
Dai HR, Liu Y, Lu KY, He X, Guo HL, Hu YH et al. Population Pharmacokinetic Modeling of Caffeine in Preterm Infants with Apnea of Prematurity: New Findings from Concomitant Erythromycin and AHR Genetic Polymorphisms. Pharmacological Research. 2022 Oct; 184: 106416. doi: 10.1016/j.phrs.2022.106416.
Khan AR, Shah SH, Ajaz S, Firasat S, Abid A, Raza A. The Prevalence of Pharmacogenomics Variants and Their Clinical Relevance among the Pakistani Population. Evolutionary Bioinformatics. 2022 Apr; 18: 11769343221095834. doi: 10.1177/11769343221095834.
Liu L, Huang X, Zhou Y, Han Y, Zhang J, Zeng F et al. CYP3A4/5 Genotypes and Age Codetermine Tacrolimus Concentration and Dosage in Pediatric Heart Transplant Recipients. International Immunopharmacology. 2022 Oct; 111: 109164. doi: 10.1016/j.intimp.2022.109164.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews. British Medical Journal. 2021 Mar; 372.
Resztak M, Zalewska P, Wachowiak J, Sobkowiak-Sobierajska A, Główka FK. Voriconazole Therapeutic Drug Monitoring Including Analysis of CYP2C19 Phenotype in Immunocompromised Pediatric Patients with Invasive Fungal Infections. European Journal of Clinical Pharmacology. 2024 Nov; 80(11): 1829-40. doi: 10.1007/s00228-024-03752-z.
Li R, Bi B, Dong Z, Chen S, Yun Y, Wang X et al. Identifying Factors Related to Sertraline Concentrations in Child/Adolescent and Adult Patients: Insights from a Therapeutic Drug Monitoring Service. BioMed Central Psychiatry. 2025 Jun; 25(1): 590. doi: 10.1186/s12888-025-07033-6.
Mahdy WY, Yamamoto K, Joji R, Hashimoto M, Nakasone R, Fujioka K et al. Evaluation of Fentanyl-Emerged Adverse Events and Pharmacokinetics in Neonates: A Physiologically Based Pharmacokinetic Modeling Approach. Clinical Pharmacokinetics. 2025 Dec; 64(12): 1811-25. doi: 10.1007/s40262-025-01573-6.
Bardol M, Norman E, Lagercrantz H, Fellman V, Standing JF. Fentanyl Dosage for Preterm Infants Suggested by a Pharmacokinetic-Dynamic and Genetic Model. Pediatric Research. 2025 Jan; 97(1): 239-45. doi: 10.1038/s41390-024-03404-z.
Conyers R, Stenta T, Somogyi AA, Kirkpatrick C, Halman A, Wang S et al. Phenoconversion of CYP3A4, CYP2C19, and CYP2D6 in Pediatrics, Adolescents, and Young Adults with Lymphoma: Rationale and Design of the PEGASUS Study. Clinical and Translational Science. 2025 Apr; 18(4): e70209. doi: 10.1111/cts.70209.
Parvez MM, Thakur A, Mehrotra A, Stancil S, Pearce RE, Basit A et al. Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling. Clinical Pharmacology and Therapeutics. 2024 Oct; 116(4): 1090-9. doi: 10.1002/cpt.3354.
Leeder JS, Dinh JC, Gaedigk A, Staggs VS, Prasad B, Pearce RE. Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver. Drug Metabolism and Disposition. 2022 Jan; 50(1): 24-32. doi: 10.1124/dmd.121.000623.
He X, Qiu JC, Lu KY, Guo HL, Li L, Jia WW et al. Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants. Advances in Therapy. 2021 Jan; 38(1) :607-26. doi: 10.1007/s12325-020-01544-2.
Rodieux F, Daali Y, Rollason V, Samer CF, Ing Lorenzini K. Practice of CYP450 Genotyping and Phenotyping in Children in A Real-Life Setting. Frontiers in Pharmacology. 2023 Feb; 14: 1130100. doi: 10.3389/fphar.2023.1130100.
Yalçin N, Flint RB, Van Schaik RH, Simons SH, Allegaert K. The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review. Pharmacogenomics and Personalized Medicine. 2022 Jun: 675-96. doi: 10.2147/PGPM.S350205.
Roberts TA, Wagner JA, Sandritter T, Black BT, Gaedigk A, Stancil SL. Retrospective Review of Pharmacogenetic Testing at an Academic Children’s Hospital. Clinical And Translational Science. 2021 Jan; 14(1): 412-21. doi: 10.1111/cts.12895.
Thuy LL, Nguyen LT, Vu HA, Nguyen NA, Nguyen TA. Effect of MDR1 C3435T and CYP2C19 Genetic Polymorphisms on the Outcome of Helicobacter Pylori Eradication Treatment in Children with Gastritis and Peptic Ulcer, Vietnam. BMC Pediatrics. 2024 Jul; 24(1): 464. doi: 10.1186/s12887-024-04581-w.
Van Groen BD, Pilla Reddy V, Badée J, Olivares‐Morales A, Johnson TN, Nicolaï J et al. Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium. Clinical and Translational Science. 2021 Jan; 14(1): 29-35. doi: 10.1111/cts.12843.
Magliocco G and Daali Y. Modern Approaches for the Phenotyping of Cytochrome P450 Enzymes in Children. Expert Review of Clinical Pharmacology. 2020 Jul; 13(7): 671-4. doi: 10.1080/17512433.2020.1779057.
Giangreco NP and Tatonetti NP. A Database of Pediatric Drug Effects to Evaluate Ontogenic Mechanisms from Child Growth and Development. Medicine. 2022 Aug; 3(8): 579-95. doi: 10.1016/j.medj.2022.06.001.
Wiebe ST, Meid AD, Mikus G. Composite Midazolam and 1′-OH Midazolam Population Pharmacokinetic Model for Constitutive, Inhibited and Induced CYP3A Activity. Journal of Pharmacokinetics and Pharmacodynamics. 2020 Dec; 47(6): 527-42. doi: 10.1007/s10928-020-09704-1.
Vander Schaaf M, Luth K, Townsend DM, Chessman KH, Mills CM, Garner SS et al. CYP3A4 Drug Metabolism Considerations in Pediatric Pharmacotherapy. Medicinal Chemistry Research. 2024 Dec; 33(12): 2221-35. doi: 10.1007/s00044-024-03360-7.
Takahashi T, Mohamud MA, Smith AR, Jacobson PA, Jaber MM, Alharbi AF et al. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children After Hematopoietic Cell Transplantation. Antimicrobial Agents and Chemotherapy. 2021 Aug; 65(9): 10-128. doi: 10.1128/AAC.00623-21.
Milosavljević F, Manojlović M, Matković L, Molden E, Ingelman-Sundberg M, Leucht S et al. Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs: A Systematic Review and Meta-Analysis. Journal of the American Medical Association Network Open. 2024 Aug; 7(8): e2425593. doi: 10.1001/jamanetworkopen.2024.25593.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
